Abstract
Interleukin (IL)-5 plays an important role in development, recruitment, and survival of eosinophils, thereby causing debilitating signs and symptoms associated with severe eosinophilic asthma. Mepolizumab is a humanized monoclonal antibody (mAb) against IL-5 which selectively inhibits eosinophilic inflammation and reduces the amount of eosinophils. This reduction is seen in both sputum and blood, resulting in a reduction in exacerbations and in time the need for using systemic steroids. The role of mepolizumab and its effect is still not fully known as there are less real-life studies available. We herewith present a case of severe eosinophilic asthma with vocal polyp managed by mepolizumab.